#biomarkertesting | Explore Tumblr Posts and Blogs

aipidia · 9 months

Text

0 notes

market-insider · 10 months

Text

Biomarker Testing Services: Transforming Healthcare Delivery and Patient Outcomes

The global biomarker testing services market size is expected to reach USD 1,399.4 million by 2030. Growing investment in pharmaceutical R&D, increasing demand for the precision medicine used for cancer treatment, and growing burden of the infectious and chronic diseases facilitating the demand for the biomarker testing are some of the major factors driving the market's growth.

Gain deeper insights on the market and receive your free copy with TOC now @: Biomarker Testing Services Market Report Report

There has been a consistent rise in clinical trials during the last 5 years. For instance, according to ClinicalTrials.gov, more than 262,298 trials were registered in 2018, whereas as of September 2022, above 399,518 trials were registered. Clinical trials are expected to improve in the coming years owing to the increase in funding for clinical research. This is expected to boost demand for medicine discovery research activities and thus support demand for biomarker testing in the post-pandemic period.

The FDA approval rate for medicines through the use of biomarkers has improved, over the years. For instance, in 2016, more than 26 trials were approved by the FDA that used biomarkers for medicine testing, whereas, in 2019, 36 trials were approved by the FDA that used biomarkers for medical testing. Clinical trials now require biomarker-related data for medicine approvals, as it provides information about the action of medicine in the body and thus speeds up the medicine approval process. This is expected to improve demand for biomarker testing during the forecast period.

Various biopharmaceutical companies are taking initiatives to improve the diagnosis rate of the cancer patient through biomarker testing. For instance, in April 2021, a biopharmaceutical company, Amgen launched the Biomarker Assist Program. As per this program, patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) were provided biomarker testing, to check the presence of oncogene biomarkers, which help in targeted therapies. Such initiatives by the market players are likely to support the market's growth.

According to the IQVIA, report on oncology trends, clinical trials for cancer have been increasing for the last 10 years. For instance, in 2011, 1,242 trials were registered for cancer, and as of 2021, 2,335 trials were registered for cancer. The number of clinical trials intended for cancer is expected to rise even further owing to the growing prevalence of the disease. There is an increasing demand for targeted therapies designed for cancer that use biomarkers for testing the efficacy of the drug in the research. Increased cancer research in the coming years is expected to boost demand for the biomarkers designed for cancer testing and thus support the market in the post-pandemic period.

0 notes

symbiosisonlinepublishing · 10 months

Text

𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬: Biosensors can be used to detect and measure levels of specific molecules in blood, urine, and other bodily fluids. This information can be used to diagnose diseases, monitor the progression of diseases, and track the effectiveness of treatment. 𝐄𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭𝐚𝐥 𝐦𝐨𝐧𝐢𝐭𝐨𝐫𝐢𝐧𝐠: Biosensors can be used to detect and measure pollutants in air, water, and soil. This information can be used to track the levels of pollutants in the environment, and to identify sources of pollution.

Visit: https://symbiosisonlinepublishing.com/biosensors-biomarkers-diagnostics/

0 notes

drekingreen · 4 years

Text

IQWiG identifiziert keine weiteren Biomarkertests zur Entscheidung über eine Chemotherapie bei Brustkrebs

http://dlvr.it/RQwh6z

0 notes

patentanwalt-reinert · 7 years

Link

Das Biotechnologie-Unternehmen PEPperPRINT GmbH teilt mit, dass es gemeinsam mit der PROGEN Biotechnik GmbH einen neuartigen Biomarkertest zur frühen und differenzierten Diagnostik der rheumatoiden Arthritis (RA) entwickeln wird. Das Projekt wird in den kommenden drei Jahren vom Bundesministerium fü...

#FacebookPages

0 notes

aipidia · 9 months

Text

0 notes

drekingreen · 4 years

Text

IQWiG identifiziert keine weiteren Biomarkertests zur Entscheidung über eine Chemotherapie bei Brustkrebs

http://dlvr.it/RQwg3m

0 notes

drekingreen · 4 years

Text

#IQWiG IQWiG identifiziert keine weiteren Biomarkertests zur Entscheidung über eine Chemotherapie bei Brustkrebs

http://dlvr.it/RQwg0m

0 notes

drekingreen · 4 years

Text

#IQWiG IQWiG identifiziert keine weiteren Biomarkertests zur Entscheidung über eine Chemotherapie bei Brustkrebs

http://dlvr.it/RQwdh8

0 notes

drekingreen · 4 years

Text

IQWiG identifiziert keine weiteren Biomarkertests zur Entscheidung über eine Chemotherapie bei Brustkrebs

http://dlvr.it/RQwdhZ

0 notes

drekingreen · 4 years

Text

IQWiG identifiziert keine weiteren Biomarkertests zur Entscheidung über eine Chemotherapie bei Brustkrebs

http://dlvr.it/RQwcfQ

0 notes

drekingreen · 4 years

Text

#IQWiG IQWiG identifiziert keine weiteren Biomarkertests zur Entscheidung über eine Chemotherapie bei Brustkrebs

http://dlvr.it/RQwcc7

0 notes

drekingreen · 4 years

Text

#IQWiG IQWiG identifiziert keine weiteren Biomarkertests zur Entscheidung über eine Chemotherapie bei Brustkrebs

http://dlvr.it/RQwbbt

0 notes

drekingreen · 4 years

Text

IQWiG identifiziert keine weiteren Biomarkertests zur Entscheidung über eine Chemotherapie bei Brustkrebs

http://dlvr.it/RQwbgx

0 notes

drekingreen · 4 years

Text

IQWiG identifiziert keine weiteren Biomarkertests zur Entscheidung über eine Chemotherapie bei Brustkrebs

http://dlvr.it/RQwZLz

0 notes

drekingreen · 4 years

Text

#IQWiG IQWiG identifiziert keine weiteren Biomarkertests zur Entscheidung über eine Chemotherapie bei Brustkrebs

http://dlvr.it/RQwZLB

0 notes